Cilostazol mitigates mesenteric ischemia/reperfusion-induced lung lesion: Contribution of PPAR-gamma, NF-kappa B, and STAT3 crosstalk

摘要

Aims: Cilostazol (Cilo), a phosphodiesterase-III inhibitor, has signified its efficacy against different ischemia/ reperfusion (IS/RE) models. Nevertheless, it has not fully illuminated its potential effect against intestinal IS/REinduced lung injury. Consequently, the study was fashioned to evaluate the feasible mechanism of action of Cilo against intestinal IS/RE-induced lung injury.